31.19
Precedente Chiudi:
$31.33
Aprire:
$30.89
Volume 24 ore:
299.94K
Relative Volume:
0.25
Capitalizzazione di mercato:
$2.39B
Reddito:
$13.17M
Utile/perdita netta:
$-199.06M
Rapporto P/E:
-11.38
EPS:
-2.74
Flusso di cassa netto:
$-156.53M
1 W Prestazione:
-1.36%
1M Prestazione:
-0.95%
6M Prestazione:
-21.99%
1 anno Prestazione:
-28.76%
Xenon Pharmaceuticals Inc Stock (XENE) Company Profile
Nome
Xenon Pharmaceuticals Inc
Settore
Industria
Telefono
(604) 484-3300
Indirizzo
200 - 3650 GILMORE WAY, BURNABY
Confronta XENE con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
XENE
Xenon Pharmaceuticals Inc
|
31.19 | 2.40B | 13.17M | -199.06M | -156.53M | -2.74 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
476.95 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
572.39 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
325.64 | 42.41B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
575.42 | 34.96B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
294.83 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Xenon Pharmaceuticals Inc Stock (XENE) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-05-07 | Iniziato | Chardan Capital Markets | Buy |
2025-02-11 | Iniziato | Deutsche Bank | Buy |
2024-10-10 | Ripresa | Raymond James | Outperform |
2024-10-01 | Iniziato | H.C. Wainwright | Buy |
2024-01-04 | Iniziato | Citigroup | Buy |
2023-12-08 | Iniziato | Robert W. Baird | Outperform |
2023-10-24 | Ripresa | Cantor Fitzgerald | Overweight |
2023-04-25 | Iniziato | Cantor Fitzgerald | Overweight |
2022-12-14 | Iniziato | Goldman | Buy |
2022-12-12 | Iniziato | Cowen | Outperform |
2022-11-28 | Iniziato | Wells Fargo | Overweight |
2022-10-19 | Iniziato | Raymond James | Outperform |
2022-08-29 | Iniziato | BofA Securities | Buy |
2022-07-21 | Iniziato | JP Morgan | Overweight |
2021-10-28 | Iniziato | RBC Capital Mkts | Outperform |
2020-10-02 | Iniziato | SVB Leerink | Outperform |
2020-07-21 | Iniziato | Needham | Buy |
2020-06-01 | Ripresa | Jefferies | Buy |
2020-03-25 | Iniziato | Wedbush | Outperform |
2020-01-08 | Iniziato | William Blair | Outperform |
2019-09-20 | Iniziato | Guggenheim | Buy |
2018-08-08 | Reiterato | Stifel | Buy |
2017-03-13 | Iniziato | Jefferies | Buy |
2016-10-21 | Iniziato | Stifel | Buy |
2016-09-26 | Iniziato | Guggenheim | Buy |
2016-04-14 | Reiterato | Jefferies | Buy |
2015-10-30 | Ripresa | Jefferies | Buy |
2014-12-02 | Iniziato | Canaccord Genuity | Buy |
Mostra tutto
Xenon Pharmaceuticals Inc Borsa (XENE) Ultime notizie
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Bought by Bank of New York Mellon Corp - Defense World
How Xenon Pharmaceuticals Inc. stock performs during market volatilityFree Access to Community - Newser
Xenon Pharmaceuticals Inc. Stock Analysis and ForecastFree Bull & Bear Market Updates - jammulinksnews.com
Is Xenon Pharmaceuticals Inc. a good long term investmentFree Stock Selection - jammulinksnews.com
What drives Xenon Pharmaceuticals Inc. stock priceHigh-octane financial growth - jammulinksnews.com
What analysts say about Xenon Pharmaceuticals Inc. stockRapid profit acceleration - jammulinksnews.com
Mutual of America Capital Management LLC Buys New Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
Should I buy Xenon Pharmaceuticals Inc. stock before earningsFree Smart Money Stock Analysis - Newser
(XENE) Investment Analysis and Advice - news.stocktradersdaily.com
Teacher Retirement System of Texas Reduces Stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
Why Xenon Pharmaceuticals Inc. stock attracts strong analyst attentionReliable High Profit Alerts - Newser
What makes Xenon Pharmaceuticals Inc. stock price move sharplyHigh Yield Opportunities - Newser
We're Hopeful That Xenon Pharmaceuticals (NASDAQ:XENE) Will Use Its Cash Wisely - Yahoo Finance
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Average Recommendation of “Buy” by Brokerages - Defense World
Traders Buy Large Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE) - Defense World
How to Take Advantage of moves in (XENE) - news.stocktradersdaily.com
CFO changes at Biocryst, Xenon, Century, Pyxis - biocentury.com
RBC Raises Xenon Price Target, Cites Phase III Optimism for Epilepsy Drug - MSN
Xenon Appoints CEO Ian Mortimer as Interim CFO - The Globe and Mail
XENE CEO Named Interim CFO After Sherry Aulin Resigns | XENE SEC FilingForm 8-K - Stock Titan
Xenon Pharmaceuticals Inc.(NasdaqGM:XENE) added to Russell Small Cap Comp Growth Index - MarketScreener
Xenon Pharmaceuticals: Riding the Russell Wave to Institutional Inflows and Clinical Milestones? - AInvest
Xenon Joins the Russell 3000® and Russell 2000® Indexes - The Manila Times
Xenon Pharmaceuticals added to Russell 3000 and 2000 indexes - Investing.com India
Xenon Pharmaceuticals Inc. Added to Russell 3000® and Russell 2000® Indexes in Annual Reconstitution - Quiver Quantitative
Xenon Pharmaceuticals Announces Equity Inducement Grants to New Employees - TipRanks
Is Xenon Pharmaceuticals, Inc. overvalued or undervalued? - MarketsMojo
Xenon Announces Appointment of Darren Cline as Chief Commercial Officer - The Globe and Mail
Long Term Trading Analysis for (XENE) - news.stocktradersdaily.com
Xenon Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:XENE) - MarketBeat
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Average Recommendation of “Buy” from Analysts - Defense World
RBC Capital Maintains Xenon Pharmaceuticals(XENE.US) With Buy Rating, Raises Target Price to $57 - 富途牛牛
Xenon Pharmaceuticals price target raised to $57 from $55 at RBC Capital - Investing.com Canada
RBC Raises Price Target on Xenon Pharmaceuticals to $57 From $55, Keeps Outperform, Speculative Risk - MarketScreener
Cantor Fitzgerald Estimates XENE FY2026 Earnings - MarketBeat
Traders Purchase High Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE) - Defense World
Xenon Pharmaceuticals (XENE) Up 8.7% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Brokers Set Expectations for XENE FY2026 Earnings - Defense World
Xenon Pharmaceuticals at Goldman Sachs Conference: Strategic Clinical Advances By Investing.com - Investing.com Canada
Xenon Pharmaceuticals Inc Azioni (XENE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):